The FDA has granted accelerated approval to selpercatinib (Retevmo, Lilly) for several indications, marking the first FDA approval of a targeted therapy for pediatric patients <12 years of age with RET alterations.
The new accelerated approval covers patients 2 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and are